Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome

Yasuyo Kashiwagi; Hisashi Kawashima; Shigeo Nishimata; Ryuhei Nagao; Kiyoko Watanabe; Kouji Takekuma; Akinori Hoshika

doi:10.1007/s10067-007-0734-7

Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome

Clin Rheumatol. 2008 Feb;27(2):277-9. doi: 10.1007/s10067-007-0734-7. Epub 2007 Sep 22.

Authors

Yasuyo Kashiwagi¹, Hisashi Kawashima, Shigeo Nishimata, Ryuhei Nagao, Kiyoko Watanabe, Kouji Takekuma, Akinori Hoshika

Affiliation

¹ Department of Pediatrics, Tokyo Medical University, Tokyo, Japan. [email protected]

PMID: 17891446
DOI: 10.1007/s10067-007-0734-7

Abstract

We describe a case of severe CINCA syndrome in a Japanese male infant. We recently managed with anti-interleukin 1 agent (anakinra). Anakinra immediately led to improvement of both the clinical symptoms and the laboratory findings.

Publication types

Case Reports

MeSH terms

Antirheumatic Agents / therapeutic use*
Child
Exanthema / drug therapy*
Humans
Infant, Newborn
Infant, Newborn, Diseases / drug therapy
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Joint Diseases / drug therapy*
Male
Meningitis / drug therapy*
Severity of Illness Index
Syndrome

Substances

Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein